Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis

Bai,Xiaodong; Meng,Hai; Ma,Lifeng; Guo,Ai

doi:10.3892/ol.2014.2791

Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis

Authors:
- Xiaodong Bai
- Hai Meng
- Lifeng Ma
- Ai Guo
View Affiliations

Affiliations: Department of Orthopedics, Beijing Friendship Hospital, Capital Medical University, Xicheng, Beijing 100050, P.R. China
Published online on: December 11, 2014 https://doi.org/10.3892/ol.2014.2791
Pages: 801-805

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is a primary malignancy of bone, which is characterized by the proliferation of malignant mesenchymal cells, particularly in children and adolescents. Evodiamine is extracted from a variety of traditional Chinese medicines, which has been reported to induce apoptosis in certain tumors, including cervical, prostate and breast cancer, however, its effect on oestosarcoma cells remains unclear. The aim of the present study was to investigate the effect of evodiamine on osteosarcoma cell proliferation and apoptosis, and explore the associated underlying molecular mechanism. A Cell Counting Kit 8 assay was performed to detect the effects of evodiamine on the proliferation of human osteosarcoma U2OS cells. Annexin V‑fluorescein isothiocyanate/propidium iodide staining was performed to analyze the apoptotic rate of the cells. The effect of evodiamine on the protein expression levels of B‑cell lymphoma‑2 (Bcl‑2), Bcl‑2‑associated X protein (Bax), caspase‑3 and survivin were detected by performing western blot analysis. Evodiamine inhibited the growth of human osteosarcoma U2OS cells by inhibiting cell proliferation and inducing cell apoptosis. Western blotting demonstrated that evodiamine downregulated the expression of Bcl‑2, caspase‑3 and survivin, and upregulated the expression of Bax in human osteosarcoma cells. Evodiamine effectively inhibited proliferation and induced apoptosis of osteosarcoma cells in a dose‑dependent manner via downregulation of Bcl‑2, caspase‑3 and survivin protein expression levels and upregulation of Bax protein expression levels.

View Figures

View References

1	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
2	Osaki M, Takeshita F, Sugimoto Y, et al: MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 19:1123–1130. 2011. View Article : Google Scholar : PubMed/NCBI
3	Federman N, Bernthal N, Eilber FC and Tap WD: The multidisciplinary management of osteosarcoma. Curr Treat Option Oncol. 10:82–93. 2009. View Article : Google Scholar
4	Salah S, Ahmad R, Sultan I, et al: Osteosarcoma with metastasis at initial diagnosis: Current outcomes and prognostic factors in the context of a comprehensive cancer center. Mol Clin Oncol. 2:811–816. 2014.PubMed/NCBI
5	Qu JT, Wang M, He HL, Tang Y and Ye XJ: The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol. 138:819–825. 2012. View Article : Google Scholar : PubMed/NCBI
6	Nagarajan R, Kamruzzaman A, Ness KK, et al: Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. Cancer. 117:625–634. 2011. View Article : Google Scholar :
7	Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
8	Jia L, Ma S, Hou X, et al: The synergistic effects of traditional Chinese herbs and radiotherapy for cancer treatment. Oncol Lett. 5:1439–1447. 2013.PubMed/NCBI
9	Shi RX, Ong CN and Shen HM: Luteolin sensitizes tumor necrosis factor-α-induced apoptosis in human tumor cells. Oncogene. 23:7712–7721. 2004. View Article : Google Scholar : PubMed/NCBI
10	Lin SY, Liu JD, Chang HC, et al: Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem. 84:532–544. 2002. View Article : Google Scholar : PubMed/NCBI
11	Chiou WF, Chou CJ, Shum AY and Chen CF: The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action. Eur J Pharmacol. 215:277–283. 1992. View Article : Google Scholar : PubMed/NCBI
12	Choi YH, Shin EM, Kim YS, Cai XF, Lee JJ and Kim HP: Anti-inflammatory principles from the fruits of Evodia rutaecarpa and their cellular action mechanisms. Arch Pharm Res. 29:293–297. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kobayashi Y: The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med. 69:425–428. 2003. View Article : Google Scholar : PubMed/NCBI
14	Fei XF, Wang BX, Li TJ, et al: Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci. 94:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Wu LJ, Tashiro S, Onodera S and Ikejima T: Evodiamine induces tumor cell death through different pathways: apoptosis and necrosis. Acta Pharmacol Sin. 25:83–89. 2004.PubMed/NCBI
16	Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ and Wang PS: Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J Cell Biochem. 101:44–56. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kan SF, Huang WJ, Lin LC and Wang PS: Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer. 110:641–651. 2004. View Article : Google Scholar : PubMed/NCBI
18	Liao CH, Pan SL, Guh JH, et al: Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis. 26:968–975. 2005. View Article : Google Scholar : PubMed/NCBI
19	Zhang Y, Wu LJ, Tashiro S, Onodera S and Ikejima T: Evodiamine induces A375-S2 cell death through two different pathways. Yao Xue Xue Bao. 38:650–653. 2003.(In Chinese).
20	Huang YC, Guh JH and Teng CM: Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. Life Sci. 75:35–49. 2004. View Article : Google Scholar : PubMed/NCBI
21	Hockenbery DM, Oltvai ZN, Yin XM, et al: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 75:241–251. 1993. View Article : Google Scholar : PubMed/NCBI
22	Antonsson B: Bax and other pro-apoptotic Bcl-2 family “killer-proteins” and their victim the mitochondrion. Cell Tissue Res. 306:347–361. 2001. View Article : Google Scholar : PubMed/NCBI
23	Jiang J and Hu C: Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules. 14:1852–1859. 2009. View Article : Google Scholar : PubMed/NCBI
24	Brunelle JK and Letai A: Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 122:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
25	Fiandalo MV and Kyprianou N: Caspase control: protagonists of cancer cell apoptosis. Exp Oncol. 34:165–175. 2012.PubMed/NCBI
26	Yang J, Liu X, Bhalla K, et al: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
27	Siu WP, Pun PB, Latchoumycandane C and Boelsterli UA: Bax-mediated mitochondrial outer membrane permeabilization (MOMP), distinct from the mitochondrial permeability transition, is a key mechanism in diclofenac-induced hepatocyte injury: Multiple protective roles of cyclosporin A. Toxicol Appl Pharmacol. 227:451–461. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R and Zhou T: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene. 22:2034–2044. 2003. View Article : Google Scholar : PubMed/NCBI
29	Swanton E, Savory P, Cosulich S, et al: Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in cytosolic extracts. Oncogene. 18:1781–1787. 1999. View Article : Google Scholar : PubMed/NCBI
30	Park JW, Choi YJ, Suh SI, et al: Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis. 22:1633–1639. 2001. View Article : Google Scholar : PubMed/NCBI
31	Osaka E, Suzuki T, Osaka S, et al: Survivin expression levels as independent predictors of survival for osteosarcoma patients. J Orthop Res. 25:116–121. 2007. View Article : Google Scholar
32	Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 22:8581–8589. 2003. View Article : Google Scholar : PubMed/NCBI
33	Lu CD, Altieri DC and Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 58:1808–1812. 1998.PubMed/NCBI
34	Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 6:127–134. 2000.PubMed/NCBI
35	Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58:5071–5074. 1998.PubMed/NCBI
36	Tamm I, Wang Y, Sausville E, et al: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315–5320. 1998.PubMed/NCBI
37	Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar
38	Suzuki A and Shiraki K: Tumor cell ‘dead or alive’: caspase and survivin regulate cell death, cell cycle and cell survival. Histol Histopathol. 16:583–593. 2001.PubMed/NCBI